
    
      Study LVM-MD-11 is a randomized, double-blind, placebo- and active-controlled, parallel
      group, fixed-dose study in adolescent patients, ages 12-17 years. The study will be
      approximately 10 weeks in duration:

        -  1-week screening/washout period

        -  8-week double-blind treatment period

        -  1-week double-blind down-taper period

      Participants who meet the eligibility criteria at Visit 2 (Baseline) will be randomized to 1
      of 4 treatment groups: placebo, levomilnacipran 40 mg/day, levomilnacipran 80 mg/day, or
      fluoxetine 20 mg/day.
    
  